Ligand is a high-growth company with economic rights to some of the world's most important medicines.
Ligand’s portfolio covers a diverse array of therapeutic areas, partners and underlying technologies with many products in late stage development.
Ligand’s investment in new technology has resulted in cutting-edge innovations that are making major drugs possible.
Ligand has multiple technologies and unpartnered programs available for out-licensing.
Nov 9, 2021 • 4:02 PM EST
Ligand Reports Third Quarter 2021 Financial Results
Nov 9, 2021 • 4:01 PM EST
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
Oct 26, 2021 • 4:01 PM EDT
Ligand to Report Third Quarter Financial Results on November 9, 2021
Nov 9, 2021 • 4:30pm EST
See all events
Jul 29, 2021 • 4:30pm EST
Jun 4, 2021 • 8:30am PST